BioLineRx Business Summary

BioLineRx Ltd. (BLRX) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for oncology and rare diseases. The company generates revenue through a capital-efficient licensing model, primarily driven by high-margin royalties (ranging from 18% to 23%) and milestone payments from its lead FDA-approved product, APHEXDA (motixafortide), which is out-licensed to Ayrmid Ltd. for global markets and Gloria Biosciences for Asia. Its primary business segments focus on stem cell mobilization for multiple myeloma and advancing a clinical pipeline that includes Phase 2b trials for metastatic pancreatic cancer and the development of GLIX1 for glioblastoma through a joint venture with Hemispherian AS. Within the competitive landscape, BioLineRx contends with peers such as MiNK Therapeutics, MIRA Pharmaceuticals, and CervoMed, positioning itself as a lean, royalty-driven entity that has successfully transitioned from high-burn R&D to a sustainable commercial-licensing framework. Originally founded in 2003 through a consortium including Teva Pharmaceutical Industries and leading venture capital firms, the company is currently led by Chief Executive Officer Philip A. Serlin, who previously served as the firm’s CFO/COO and held senior roles at Deloitte and the U.S. Securities and Exchange Commission (SEC). The executive team is supported by Chief Financial Officer Mali Zeevi, formerly of PwC and Tescom, and Chief Development Officer Ella Sorani, PhD, who oversees the technical advancement of the oncology pipeline. The Board of Directors is chaired by Aharon Schwartz, PhD, a veteran of Teva’s executive leadership, and includes notable members such as Sandra Panem and BJ Bormann. The company maintains a diverse institutional investor base, with significant positions held by firms such as Susquehanna International Group, Highbridge Capital Management, and Citadel Advisors.